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Cell-cycle transitions are
regulated by the periodic activities
of a family of closely related
enzymes, the cyclin-dependent
kinases. In yeast, this is
accomplished by a single cyclin-
dependent kinase, whereas
mammalian cells have evolved
multiple cyclin-dependent
kinases, presumably to
accommodate the increased need
for cell-cycle control required by
complex organisms. Monomeric
cyclin-dependent kinases are
catalytically inactive, and are
activated by regulatory subunits
termed cyclins. Cyclins not only
activate but also direct their
partner cyclin-dependent kinases
to substrates, the phosphorylation
of which leads to cell-cycle
progression. 
In mammalian cells, G1
progression is controlled by D-type
cyclins which activate the cyclin-
dependent kinases CDK4 and
CDK6, followed by the activities of
cyclin E–CDK2 and cyclin A–CDK2,
which regulate entry into, and
progression through, S phase.
Finally, cyclin A–CDK1 and cyclin
B–CDK1 control mitotic entry and
exit (Figure 1). The concerted
activity of these multiple and
distinct cyclin–CDK complexes has
been thought to be a fundamental
requirement for mammalian cell
division [1].
This dogma has been slowly
eroded by studies with knockout
mice which have shown that most
cell-cycle proteins are
dispensable for mouse
development or cell proliferation
[2]. However, the central role of
cyclin E–CDK2 in regulating
S-phase entry remained secure
until several recent lines of
evidence indicated that it too
might be dispensable for cell
division. First, studies in cell lines
using RNA interference suggested
that tumor cells can proliferate
without CDK2 activity [3]. Shortly
thereafter, two groups [4,5]
demonstrated that CDK2 null mice
are viable and essentially normal
except for meiotic difficulties.
Surprisingly, although most
workers assumed that another
cyclin-dependent kinase
substituted for the loss of CDK2 in
these mice, no cyclin E-
associated kinase activity could
be detected in CDK2 null cells,
raising the possibility that neither
cyclin E nor CDK2 is required for
most types of cell division in
mammals.
The plot thickened when the
Sicinski [6] and Amati [7] labs
reported that mice lacking cyclin
E exhibit phenotypes quite
distinct from that of CDK2 null
animals. Cyclin E null mice and
cells are largely normal until birth,
supporting the idea that cyclin
E–CDK2 is not absolutely required
for mammalian mitotic cell cycles.
But cyclin E null cells exhibit
important phenotypes not seen in
CDK2 null cells, including a failure
to renter the cell cycle from
quiescence, resistance to
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was stimulated. The interest of
Hosoya et al. [2] is in the first
case, in which the retina would
carry out a plastic adjustment to
the statistics of a whole
environment. In that case,
adaptation to vertical bars could
be seen as mimicking adaptation
to the forest environment:
responses to any vertical line
would be reduced. 
On the other hand, adaptation
to a particular pattern of vertical
bars could represent no more
than adaptation of a particular set
of stimulated retinal neurons, in
which case adaptation would only
affect responses to that particular
pattern. An experiment seeking
adaptation to a more generalized
stimulus — a pattern of vertical
bars whose location jittered
unpredictably – yielded far
weaker evidence of pattern
specific adaptation.
The second missing piece is
that dynamic predictive coding
was shown by about half of the
retina’s ganglion cells, but little is
known about which types of cells
they were. Different types of
ganglion cell specialize in different
characteristics of the visual input
— some report on brightness,
some color, some movement, and
so on. Did some types of cell
adapt and others not? Which
kinds of cells adapt to oriented
lines and which to temporal
sequences? To answer these
questions is surely an important
step between the proof of
principle attempted here and a
concrete understanding of the
mechanism’s role in vision. Stay
tuned.
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Cell Cycle: How Cyclin E Got Its
Groove Back
CDK1 has long been known to orchestrate the passage of mammalian
cells into and through mitosis. Recent work revisits the idea that CDK1,
in conjunction with cyclin E, participates in S-phase entry as well. The
new results shed light on a recent cell-cycle mystery, and provide
another dramatic example of apparent functional redundancy among




(the latter leading to early
embryonic death, which was
overcome by breeding
techniques). 
The discordance in the
phenotypes resulting from
deletion of either cyclin E or
CDK2 led to a major problem. As
cyclins are believed to exert their
biological activities primarily
through cyclin-dependent kinase
activation, shouldn’t the CDK2
null mice — in which no cyclin E-
associated kinase activity was
found — and cyclin E null mice
share important phenotypes? If
not, does this mean that cyclin E
performs physiological functions
that are independent of cyclin-
dependent kinase activity? This
latter point gained support from a
study [8] indicating that cyclin E
might initiate S-phase entry via
an undefined role in
centrosomes, rather than by
activating CDK2.
Many of these issues have now
been addressed in a report [9]
indicating that cyclin E–CDK1 can
regulate the G0/G1 and G1/S
transitions and is redundant with
cyclin E–CDK2. This finding is
both reassuring and surprising.
Firstly, by demonstrating that
CDK1 compensates for the
absence of CDK2, this work
provides comfort to traditionalists
who recoil at the possibility that
cyclin E’s essential functions are
CDK-independent. 
But this study [9] also provides
evidence for a surprising level of
plasticity in cell-cycle regulation.
The importance of the cyclin
E–CDK1 complex was unmasked
by combining the CDK2 null
mutation with deletion of the
cyclin-dependent kinase inhibitor
p27. In fact, two labs
independently generated double
knockout mice that lacked both
CDK2 and p27 [9,10]. The goal of
this work was initially to determine
the role of deregulated CDK2
activity in the striking phenotypes
of p27 null mice, which include
large body size, cell
hyperproliferation, and pituitary
tumors [11–13]. 
The Kaldis [9] and Barbacid [10]
groups both generated double
knockout mice to test the
prediction that CDK2 ablation
would revert the p27 null
phenotypes. This was not the
case, however, as the double
knockout mice were found to
display all of the p27 null
aberrations. Thus, if
unconstrained CDK2 activity does
not produce the p27 null
phenotypes, could there be
another p27-regulated kinase?
This possibility was supported by
the observation [10] that the
proliferation of normal and CDK2
null cells is equally sensitive to
inhibition by p27.
However, unlike previous
studies in CDK2 null mice, in
which cyclin E-associated kinase
activity could not be detected,
Aleem et al. [9] found significant
amounts of cyclin E-associated
kinase activity in the double
knockout cells, indicating that
cyclin E indeed activates another
kinase in the absence of CDK2
that is inhibited by p27. They
showed cyclin E binding to CDK1
in double knockout and normal
cells, and these complexes were
catalytically active. Moreover,
they found that reducing CDK1
abundance in double knockout
cells by RNA interference
inhibited S-phase entry after
mitogenic stimulation of resting
cells, supporting the idea that
cyclin E-CDK1 complexes
compensate for the lack of cyclin
E–CDK2 in these cells. Thus,
cyclin E function may require an
associated kinase after all, and
CDK2’s close relative, CDK1, may
provide this activity.
Although there have been
previous reports of cyclin E–CDK1
activity [14–17], a major role for
cyclin E–CDK1 in cell-cycle re-
entry and/or G1 progression is
surprising, as CDK1 function has
been firmly linked to the second
half of the cell cycle. But Aleem et
al. [9] uncovered detectable cyclin
E–CDK1 activity only after
deletion of p27. Is it reasonable to
conclude that because cyclin
E–CDK1 may support cell-cycle
re-entry in double knockout cells
that it plays this role in normal
cells as well? This question is
particularly important because
this putative cyclin E–CDK1
activity is below the level of
detection in normal cells. Aleem et
al. [9] addressed this question by
demonstrating that CDK1
knockdown by RNA inhibition also
inhibits S-phase entry in normal
cells — albeit to a lesser extent
than in double knockout cells —
indicating that CDK1 may play a
normal role in S-phase entry, at
least in the first cell cycle as cells
exit quiescence. 
One caveat of these studies is
that the CDK1 knockdown
experiments are also likely to
inhibit cyclin A activity, and thus
fall short of demonstrating an
essential cyclin E–CDK1 function
as normal cells enter S phase.
Nonetheless, the cell-cycle re-
entry data suggest an intriguing
new role for low levels of CDK1
activity beyond its well-described
functions in G2/M. These results
are also reminiscent of another
cell-cycle paradigm: low cyclin-
dependent kinase activity in the
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Figure 1. Cyclin–cyclin-dependent kinase complexes promote cell-cycle progression.
Schematic of the mammalian (upper part) and yeast (lower part) cell division cycle.
Unlike yeasts, which proliferate with a single cyclin-dependent kinase subunit (shown
here for budding yeast Saccharomyces cerevisiae), mammalian cells have multiple such
enzymes. Cyclin E has an essential function in re-entering the cell cycle after serum
starvation, and this has now been demonstrated to require CDK2 and/or CDK1. The
now uncovered role for CDK1 in participating in this transition is highlighted in red.
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early cell-cycle phases followed
by high cyclin-dependent kinase
activity as the cell cycle
progresses.
So, where are we left regarding
the roles of cyclin E, CDK2 and
CDK1 in cell-cycle control? Have
these findings simply shed
important light upon unresolved
issues in knockout mice, or do we
now have a fundamental revision
in mammalian cell-cycle
regulation? This answer lies in
part with the unresolved question
of whether cyclin E–CDK1
complexes have unique biological
functions, or simply are artifacts
that arise only when CDK2 is
deleted. If the latter, than this may
be yet another example of the
remarkable redundancy of the
mammalian cell cycle revealed by
knockout mice. That is, as the
complexities of mammalian cell-
cycle regulation are stripped away
by various mouse knockout
mutations, the features that
distinguish the essence of the
mammalian cell cycle from that of
yeast become less clear.
Ultimately, we may find that a
murine fibroblast can proliferate
with only a single cyclin-
dependent kinase left intact. As
with the CDK2 null mouse,
however, it is likely that such
animals would exhibit more subtle
defects in cell-cycle regulation,
and it may be these very
differences that permit the
complex proliferative control
required by multicellular
organisms. Thus, a severely
compromised mouse living
entirely on CDK1 alone may one
day reassure us of our
evolutionary advances over yeast
— from a cell-cycle point of view
at least.
References
1. Weinberg, R.A. (1995). The
retinoblastoma protein and cell cycle
control. Cell 81, 323–330.
2. Sherr, C.J., and Roberts, J.M. (2004).
Living with or without cyclins and cyclin-
dependent kinases. Genes Dev. 18,
2699–2711.
3. Tetsu, O., and McCormick, F. (2003).
Proliferation of cancer cells despite
CDK2 inhibition. Cancer Cell 3, 233–245.
4. Berthet, C., Aleem, E., Coppola, V.,
Tessarollo, L., and Kaldis, P. (2003).
Cdk2 knockout mice are viable. Curr.
Biol. 13, 1775–1785.
5. Ortega, S., Prieto, I., Odajima, J., Martin,
A., Dubus, P., Sotillo, R., Barbero, J.L.,
Malumbres, M., and Barbacid, M. (2003).
Cyclin-dependent kinase 2 is essential
for meiosis but not for mitotic cell
division in mice. Nat. Genet. 35, 25–31.
6. Geng, Y., Yu, Q., Sicinska, E., Das, M.,
Schneider, J.E., Bhattacharya, S.,
Rideout, W.M., Bronson, R.T., Gardner,
H., and Sicinski, P. (2003). Cyclin E
ablation in the mouse. Cell 114, 431–443.
7. Parisi, T., Beck, A.R., Rougier, N.,
McNeil, T., Lucian, L., Werb, Z., and
Amati, B. (2003). Cyclins E1 and E2 are
required for endoreplication in placental
trophoblast giant cells. EMBO J. 22,
4794–4803.
8. Matsumoto, Y., and Maller, J.L. (2004). A
centrosomal localization signal in cyclin
E required for Cdk2-independent S
phase entry. Science 306, 885–888.
9. Aleem, E., Kiyokawa, H., and Kaldis, P.
(2005). Cdc2-cyclin E complexes
regulate the G1/S phase transition. Nat.
Cell Biol. 7, 831–836.
10. Martin, A., Odajima, J., Hunt, S.L.,
Dubus, P., Ortega, S., Malumbres, M.,
and Barbacid, M. (2005). Cdk2 is
dispensable for cell cycle inhibition and
tumor suppression mediated by
p27(Kip1) and p21(Cip1). Cancer Cell 7,
591–598.
11. Kiyokawa, H., Kineman, R.D., Manova-
Todorova, K.O., Soares, V.C., Hoffman,
E.S., Ono, M., Khanam, D., Hayday, A.C.,
Frohman, L.A., and Koff, A. (1996).
Enhanced growth of mice lacking the
cyclin-dependent kinase inhibitor
function of p27(Kip1). Cell 85, 721–732.
12. Nakayama, K., Ishida, N., Shirane, M.,
Inomata, A., Inoue, T., Shishido, N., Horii,
I., Loh, D.Y., and Nakayama, K. (1996).
Mice lacking p27(Kip1) display increased
body size, multiple organ hyperplasia,
retinal dysplasia, and pituitary tumors.
Cell 85, 707–720.
13. Fero, M.L., Rivkin, M., Tasch, M., Porter,
P., Carow, C.E., Firpo, E., Polyak, K.,
Tsai, L.H., Broudy, V., Perlmutter, R.M.,
et al. (1996). A syndrome of multiorgan
hyperplasia with features of gigantism,
tumorigenesis, and female sterility in
p27(Kip1)-deficient mice. Cell 85,
733–744.
14. Koff, A., Cross, F., Fisher, A.,
Schumacher, J., Leguellec, K., Philippe,
M., and Roberts, J.M. (1991). Human
cyclin E, a new cyclin that interacts with
two members of the CDC2 gene family.
Cell 66, 1217–1228.
15. Lew, D.J., Dulic, V., and Reed, S.I. (1991).
Isolation of three novel human cyclins by
rescue of G1 cyclin (Cln) function in
yeast. Cell 66, 1197–1206.
16. Koff, A., Giordano, A., Desai, D.,
Yamashita, K., Harper, J.W., Elledge, S.,
Nishimoto, T., Morgan, D.O., Franza,
B.R., and Roberts, J.M. (1992).
Formation and activation of a cyclin E-
cdk2 complex during the G1 phase of
the human cell cycle. Science 257,
1689–1694.
17. Marraccino, R.L., Firpo, E.J., and
Roberts, J.M. (1992). Activation of the
p34 CDC2 protein kinase at the start of S
phase in the human cell cycle. Mol. Biol.
Cell 3, 389–401.
Fred Hutchinson Cancer Research
Center, D2-100, 1100 Fairview Avenue
N, Seattle, Washington 98109, USA.
DOI: 10.1016/j.cub.2005.09.018
Current Biology Vol 15 No 19
R812
